Risky Breast Cancer Margins; New Myeloma Therapy Shows Promise; Cancer Cell Fungus

Surgical margins <1 mm in breast-conserving surgery increased the risk of local and distant recurrence. (The BMJ)

CAR T-cell therapy targeting a form of G protein-coupled receptor achieved a high response rate in relapsed/refractory multiple myeloma, including in patients previously treated with CAR T-cell therapy targeting B-cell maturation antigen. (New England Journal of Medicine)

The FDA approved the Oncomine Dx Target Test for identifying patients with thyroid cancer associated with RET mutations/fusions suitable for treatment with selpercatinib (Retevmo), Thermo Fisher Scientific announced.

The FDA cleared the artificial intelligence-assisted Skout polyp detection device for colorectal cancer screening and surveillance, Iterative Scopes said.

Celltrion announced that the FDA approved its biosimilar to bevacizumab (Avastin) — bevacizumab-adcd (Vegzelma) — for six types of cancer.

An experimental wearable device showed early promise — in mice — for monitoring tumor size and response to treatment. (Stanford University, Science Advances)

What are fungi doing in cancer cells and how did they get there? (Cell)

What are cancer cells doing inside of other cancer cells? Hiding from the immune system. (New York Times)

More than 16,000 patients with cancer died of COVID-related complications during 2020. (American Cancer Society, JAMA Oncology)

Elevated levels of C-reactive protein prior to chemotherapy for breast cancer had a significant association with cognitive decline, reinforcing the view that inflammation plays a role in the cognitive changes. (Journal of Clinical Oncology, University of California Los Angeles)